Colorectal Cancer Clinical Trials in San Francisco

Showing 21-40 of 183 trials

GCC19CART for Patients With Metastatic Colorectal Cancer

NCT05319314

Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.

Colorectal Cancer

Lyell Immunopharma, Inc.30 participantsStarted Aug 2022

Duarte, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +1 more locations

RECRUITINGPhase 1< 1 mile

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Locally Advanced or Metastatic Solid TumorsNSCLCHNSCC+9 more

Genentech, Inc.450 participantsStarted Oct 2022

San Francisco, California, United States • Aurora, Colorado, United States • Sarasota, Florida, United States +38 more locations

GCC19CART for Patients With Metastatic Colorectal Cancer

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal Cancer Trials in Other Cities

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

A Study of MGC026 in Participants With Advanced Solid Tumors

EXoPERT EMERALD Clinical Study

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer

A Study of PHN-010 in Patients With Advanced Solid Tumors

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Other Conditions in San Francisco